Dr Henick on the Use of Neoadjuvant Atezolizumab Plus Chemotherapy in NSCLC
Brian Henick, MD, discusses the 3-year updated data from a phase 2 trial investigating treatment with neoadjuvant atezolizumab plus chemotherapy in patients with resectable non–small cell lung cancer.
Source: onclive.com